{
    "clinical_study": {
        "@rank": "23428", 
        "acronym": "AIMtoPREVENT", 
        "biospec_descr": {
            "textblock": "serum"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Longitudinal cohort of patients with chronic kidney disease followed in 3 kidney centers in\n      Ontario. The goal is to determine whether and how rates of renal disease progression are\n      affected by inflammatory markers, FGF23 levels, and genetic polymorphisms"
        }, 
        "brief_title": "Inflammatory Markers and Adverse Outcomes in Chronic Kidney Disease", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Kidney Disease", 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Renal Insufficiency, Chronic", 
                "Kidney Failure, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This longitudinal cohort study will follow 2500 prevalent Chronic Kidney Disease\n      (CKD)patients under the care of a nephrologist at 3 Southern Ontario Nephrology centres and\n      all affiliated satellite centres with an estimated Glomerular Filtration Rate (eGFR) less\n      than 60 ml/min to determine the rate of their renal disease progression over a 36 months.\n      All CKD patients older than 18 years of age may be included in this study. This study will\n      analyze, with 6 month serial measurements, conventional biochemical, hormonal and metabolic\n      parameters in addition to the demographics, clinical status, medications and blood and urine\n      samples of these patients. This study will assess the influence of inflammation on FGF23 and\n      genetic polymorphisms that may reflect the processes involved with disease progression."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients referred to a nephrologist for evaluation of CKD or those currently seen by\n             a nephrologist, with eGFR less than 60 ml/min\n\n          -  Patients that are erythropoietin treatment naive\n\n          -  Transplant patients with failing grafts requiring nephrologists follow-up\n\n          -  Patients currently not receiving RRT consenting to be in the study\n\n          -  Adults 18 years of age and older\n\n        Exclusion Criteria:\n\n          -  Functioning Organ transplant\n\n          -  Life expectancy less than 12 months\n\n          -  Patients currently receiving RRT or who will likely initiate RRT within 6 months\n\n          -  Patients unable or contraindicated to receive EPREX\u00ae as erythropoietin replacement\n             therapy for the correction of anemia related to CKD"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients in chronic kidney disease clinic setting"
            }
        }, 
        "enrollment": {
            "#text": "2530", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01974713", 
            "org_study_id": "042010"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CKD progression", 
            "Inflammation", 
            "FGF23", 
            "Genetic biomarkers"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "number_of_groups": "1", 
        "official_title": "CAN-AIM to PREVENT: CANadian Study, Assessing Inflammatory Markers to PRedict EVents in Nephrology sTudy", 
        "overall_official": {
            "affiliation": "Kidney Life Science Institute", 
            "last_name": "Paul Y Tam, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Estimated glomerular filtration rate after 3 years of follow-up in the study", 
            "measure": "Renal function at study censure", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01974713"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Development of dialysis-dependent renal failure during observation period", 
            "measure": "Dialysis-dependent renal failure", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "Institute of Kidney Lifescience Technologies", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Kidney Lifescience Technologies", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "3 Years", 
        "verification_date": "October 2013"
    }
}